Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function
- 1 November 2006
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (21), 6502-6508
- https://doi.org/10.1158/1078-0432.ccr-05-1076
Abstract
Purpose: The Calvert formula is a widely applied algorithm for the a priori dosing of carboplatin based on patients glomerular filtration rate (GFR) as accurately measured using the 51Cr-EDTA clearance. Substitution of the GFR in this formula by an estimate of creatinine clearance or GFR as calculated by formulae using serum creatinine (SCR; Cockcroft-Gault, Jelliffe, and Wright) is, however, routine clinical practice in many hospitals. The goal of this study was to validate this practice retrospectively in a large heterogeneous adult patient population. Experimental Design: Concentration-time data of ultrafilterable platinum of 178 patients (280 courses, 3,119 samples) with different types of cancer receiving carboplatin-based chemotherapy in conventional and high doses were available. Data were described with a linear two-compartment population pharmacokinetic model. Relations between SCR-based formulae for estimating renal function and carboplatin clearance were investigated. Results: None of the tested SCR-based estimates of renal function were relevantly related to the pharmacokinetic variables of carboplatin. Neither SCR (median, 51; range, 18-124 μmol/L) nor the estimated GFR using the three different formulae was related to carboplatin clearance. Conclusions: Our data do not support the application of modifications of the Calvert formula by estimating GFR from SCR in the a priori dosing of carboplatin in patients with relatively normal renal function (creatinine clearance, >50 mL/min). For targeted carboplatin exposures, the original Calvert formula, measuring GFR using the 51Cr-EDTA clearance, remains the method of choice. Alternatively, in patients with normal renal function, a flat dose based on the mean population carboplatin clearance should be administered.Keywords
This publication has 32 references indexed in Scilit:
- Cystatin C as a New Covariate to Predict Renal Elimination of DrugsClinical Pharmacokinetics, 2005
- Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatinAnnals Of Oncology, 2002
- Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective studyEuropean Journal Of Cancer, 2002
- Clinical Pharmacokinetics and Dose Optimisation of CarboplatinClinical Pharmacokinetics, 1997
- Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patientsEuropean Journal Of Cancer, 1995
- The log transformation is specialStatistics in Medicine, 1995
- The importance of modeling interoccasion variability in population pharmacokinetic analysesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Clinical Pharmacokinetics of CarboplatinClinical Pharmacokinetics, 1991
- Plasma free platinum pharmacokinetics in patients treated with high dose carboplatinEuropean Journal of Cancer and Clinical Oncology, 1987
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976